This isn’t a ‘biotech bubble,’ it’s ‘Philadelphia’s moment’ to become a center for gene therapy, says Penn-based CEO

Smart, small biotech companies — dozens in the U.S. over the last two years, including several in the Philadelphia area — have gone public before they’ve made a profit, a sale, or even a product.

Is too much money chasing too few winners? Will this end like the blowup of 2001?

“This is not a bubble,” insists Steven Nichtberger, serial start-up CEO. “It’s Philadelphia’s moment.”

Read the Full Article on the Philadelphia Inquirer

Skip to content